During cognitive co-activation, the levodopa effect was significantly smaller.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve "off" periods.
Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.
Neurology Advisor Articles
- No Difference in Neurodevelopment in Children Conceived by Assisted Reproduction
- Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease
- Treating Pain in Depression May Help Improve Cognition
- The Handoff: Your Week in Neurology News - 1/19/17
- FDA Warns of Implantable Infusion Pumps in MRI